Market Research Logo

WaferGen Biosystems, Inc. (WGBS) - Financial and Strategic SWOT Analysis Review

WaferGen Biosystems, Inc. (WGBS) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

WaferGen Biosystems, Inc. (WaferGen) is a biotechnology Company which develops, manufactures and sells systems for genomic technology solutions for single-cell analysis and clinical research. The Company’s ICELL8 Single-Cell System platform isolates single cells and process specific cells for analysis, including Next Generation Sequencing (NGS). The Company’s SmartChip platform is used for profiling and validating molecular biomarkers, and also performs singleplex PCR for one-step target and preparation for clinical NGS. Its Apollo 324 system processes DNA and RNA from clinical samples to NGS-ready libraries. The company’s technologies serve pharmaceutical and life science companies as well as clinical laboratories. It operates through its subsidiaries in Delaware, the US and Luxembourg. WaferGen is headquartered in Fremont, California, the US.

WaferGen Biosystems, Inc. Key Recent Developments

Jun 16, 2016: WaferGen Receives Notice of US Patent Allowance for SmartChip and ICELL8 Single-Cell Methods and Systems to Process Genetic Material from Multi-well Arrays
Jun 06, 2016: WaferGen Bio-systems and Takara Bio Announce Exclusive Distribution Agreement for Japan
May 10, 2016: WaferGen Bio-systems Reports Results for First Quarter 2016
May 03, 2016: WaferGen Bio-systems Announces ICELL8 Single-Cell System Placements at the European Molecular Biology Laboratory and Karolinska Institutet
Mar 08, 2016: WaferGen Bio-systems Reports Results for Fourth Quarter and Fiscal Year 2015

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
WaferGen Biosystems, Inc. - Key Facts
WaferGen Biosystems, Inc. - Key Employees
WaferGen Biosystems, Inc. - Key Employee Biographies
WaferGen Biosystems, Inc. - Major Products and Services
WaferGen Biosystems, Inc. - History
WaferGen Biosystems, Inc. - Company Statement
WaferGen Biosystems, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
WaferGen Biosystems, Inc. - Business Description
WaferGen Biosystems, Inc. - Corporate Strategy
WaferGen Biosystems, Inc. - SWOT Analysis
SWOT Analysis - Overview
WaferGen Biosystems, Inc. - Strengths
Strength - Focused Research and Development Activities
Strength - SmartChip Real-Time PCR System
WaferGen Biosystems, Inc. - Weaknesses
Weakness - History of Losses
Weakness - Process Constraints
WaferGen Biosystems, Inc. - Opportunities
Opportunity - Strategic Initiatives
Opportunity - Growing Single Cell Analysis Market
Opportunity - Growth of Next Generation Sequencing (NGS)
WaferGen Biosystems, Inc. - Threats
Threat - Changing Diagnostic Market Conditions
Threat - Stiff Competition
Threat - Uncertain R&D Outcomes
WaferGen Biosystems, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
WaferGen Biosystems, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
WaferGen Biosystems, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
WaferGen Biosystems, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
WaferGen Biosystems, Inc., Medical Equipment, Deals By Type, 2010 to YTD 2016
WaferGen Biosystems, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Jun 16, 2016: WaferGen Receives Notice of US Patent Allowance for SmartChip and ICELL8 Single-Cell Methods and Systems to Process Genetic Material from Multi-well Arrays
Jun 06, 2016: WaferGen Bio-systems and Takara Bio Announce Exclusive Distribution Agreement for Japan
May 10, 2016: WaferGen Bio-systems Reports Results for First Quarter 2016
Mar 08, 2016: WaferGen Bio-systems Reports Results for Fourth Quarter and Fiscal Year 2015
Mar 03, 2016: WaferGen Bio-systems Announces Placement of ICELL8 Single-Cell System at Neural Stem Cell Institute
Feb 17, 2016: WaferGen Announces Key Findings From Collaborators Utilizing Company’s ICELL8 Single-Cell System at AGBT 2016 General Meeting
Feb 09, 2016: WaferGen Announces ICELL8 Single-Cell System Collaborators to Present Key Results at AGBT 2016 General Meeting
Feb 02, 2016: WaferGen Bio-systems Announces Collaboration With BloodCenter of Wisconsin for High Throughput Molecular Blood Typing
Jan 28, 2016: WaferGen Bio-systems Announces 50 Percent Year-Over-Year Growth in Fourth Quarter 2015 Revenues
Dec 17, 2015: WaferGen Bio-systems Announces Publication of BGI Data in GigaScience Demonstrating Utility of WaferGen’s ICELL8 Technology for Single-Cell Analysis in Cancer Research
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
WaferGen Biosystems, Inc., Key Facts
WaferGen Biosystems, Inc., Key Employees
WaferGen Biosystems, Inc., Key Employee Biographies
WaferGen Biosystems, Inc., Major Products and Services
WaferGen Biosystems, Inc., History
WaferGen Biosystems, Inc., Subsidiaries
WaferGen Biosystems, Inc., Key Competitors
WaferGen Biosystems, Inc., Ratios based on current share price
WaferGen Biosystems, Inc., Annual Ratios
WaferGen Biosystems, Inc., Interim Ratios
WaferGen Biosystems, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
WaferGen Biosystems, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
WaferGen Biosystems, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
WaferGen Biosystems, Inc., Medical Equipment, Deals By Type, 2010 to YTD 2016
WaferGen Biosystems, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
WaferGen Biosystems, Inc., Performance Chart (2011 - 2015)
WaferGen Biosystems, Inc., Ratio Charts
WaferGen Biosystems, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
WaferGen Biosystems, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
WaferGen Biosystems, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
WaferGen Biosystems, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report